BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 6, 2026
Breaking News: BioWorld Science 2025 Year in ReviewBreaking News: BioWorld 2025 Year in ReviewBreaking News: BioWorld MedTech 2025 Year in ReviewBreaking News: Trump administration impacts continue to roil the life sciences sector
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Cancer

Perha Pharmaceuticals patents CLK1, CLK4 and/or DYRK1A inhibitors

May 25, 2023
Recent Perha Pharmaceuticals patents describe imidazolone derivatives acting as inhibitors of dual specificity protein kinase CLK1 and/or CLK4 and/or and dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). As such, they are reported to be useful for the treatment of diabetes, cancer, CDKL5 deficiency disorder, chromosome 22q13 deletion syndrome, Alzheimer’s disease, viral infections, Niemann-Pick disease type C and tauopathies, among others.
Read More
Neurology/Psychiatric

Marvel Biotechnology patent details new compounds for treatment of depression

May 25, 2023
Marvel Biotechnology Inc. has reported the identification of compounds potentially useful for the treatment of depression.
Read More
Degradation of motor neurons
Neurology/Psychiatric

Next-generation gene therapy shows superior efficacy for spinal muscular atrophy

May 25, 2023
Spinal muscular atrophy (SMA) is caused by mutations in the SMN1 gene, which encodes survival motor neuron 1, leading to reduced protein expression levels and degeneration of motor neurons in the spinal cord, with the consequent muscle atrophy. There is thus a need for new AAV gene therapies for SMA that confer better safety and efficacy.
Read More
Illustration of the inside of an eye with macular degeneration
Ocular

SKG-0106 shows durable efficacy in preclinical models of neovascular AMD

May 25, 2023
Researchers from Skyline Therapeutics (Shanghai) Co. Ltd. presented preclinical data for the new recombinant AAV vector therapeutic SKG-0106, being developed for the treatment of neovascular (wet) age-related macular degeneration (AMD).
Read More
Alpha-galactosidase enzyme
Endocrine/Metabolic

AAV9-GLA restores α-galactosidase levels in murine model of Fabry disease

May 25, 2023
Fabry disease is a metabolic disease characterized by a deficiency in the lysosomal α-galactosidase enzyme caused by mutations in the GLA gene. This leads to substrate accumulation in the lysosomes, cellular dysfunction and organ damage.
Read More
Cancer cells under magnifying glass
Cancer

Discovery of new IDO-1 inhibitors with potent anticancer activity

May 25, 2023
Researchers from Guilin Medical University (GLMU) reported the discovery and preclinical evaluation of novel indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitors as potential anticancer agents. Synthesis and optimization of a series of chromone-oxime derivatives containing piperazine sulfonamide moieties led to the identification of compound [I] as the lead IDO-1 inhibitor.
Read More
Illustration of intestines overlayed on human torso
Gastrointestinal

NTX-1175 channel blocker is effective in visceral pain models

May 25, 2023
Patients with irritable bowel syndrome (IBS) have chronic abdominal pain as a result of visceral hypersensitivity. Voltage-gated sodium channels control cellular excitability and are involved in the pathophysiology of several functional gastrointestinal disorders. Researchers from Nocion Therapeutics Inc. and the University of Oklahoma recently reported on the preclinical testing of NTX-1175, a sodium-channel blocker, in rat models of acute colonic hypersensitivity to distension.
Read More
Illustration of prescription pill bottle with DNA on the label.
Neurology/Psychiatric

Gene expression study gives clues to pain insensitivity syndrome

May 25, 2023
By Anette Breindl
Researchers have used cell culture experiments to understand how gene expression was affected in a patient with a rare pain insensitivity syndrome, and have identified a network of hundreds of genes whose expression was changed compared to sex-matched controls. Published online in the journal Brain on May 23, 2023, the research is one step toward translating a rare mutation into medications that could provide benefits for common ailments.
Read More

Other news to note for May 24, 2023

May 24, 2023
Additional early-stage research and drug discovery news in brief, from: Aerovate Therapeutics, Ceapro.
Read More
Respiratory

Complement factor B inhibitors reported in Hansoh patent

May 24, 2023
A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.
Read More
Previous 1 2 … 950 951 952 953 954 955 956 957 958 … 17948 17949 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 5, 2026.
  • Sickle cell illustration

    AND-017 increases RBC and hemoglobin in sickle cell disease

    BioWorld Science
    Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
  • 3D rendering of antibody drug conjugated with cytotoxic payload

    ADCs’ breakout 2025 and their still-unfinished potential

    BioWorld Science
    Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing